Recent years have seen a flurry of approvals and guideline updates for drugs that lower lipid levels to reduce cardiovascular risk, but there is still considerable room for improvement in implementation, according to Joe Saseen and Robert Page, PharmDs, at an Institute for Value-Based Medicine event.